Fact sheet: Aviva AXA Fram Biotech Pn

Fund information
Fund name
Aviva AXA Framlington Biotech Pn S6
Fund manager company
Aviva Life & Pensions UK Ltd
Fund type
Pension Fund
Fund managers
  • Deane Donnigansince 01/04/2010
Underlying fund
AXA Framlington Biotech
Fund objective
The aim of this Fund is to provide long-term capital growth.
Benchmark
  • NASDAQ Biotechnology
Investment style
No data available.
Investment method
No data available.
Quick stats
1 Year return
18.6%
1 Year rank in sector
184/536
Sector
PN Specialist
Yield
-
Fund size
£35m (£29m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
212
Bid price
546.31
Top in this sector
Fund name1 Year
Scot Eq Technology Pn52.9%
SIP Sanlam Gbl Fin Pn50.6%
SIP Fidelity Gbl Technology Pn49.2%
OMW Neptune Rus + Grtr Rus48.3%
FL AXA Framlington Gbl Tech AP48.2%
...more in PN Specialist

Performance snapshot

Holdings snapshot

  • USA86.2%
    UK2.9%
    Sweden2.4%
    Belgium2.4%
    Money Market2.4%
  • Biotechnology/Medical78.8%
    Pharmaceuticals13%
    Technology3.7%
    Money Market2.4%
    Electronic & Electrical Equipment1.2%
  • US Equities86.2%
    UK Equities2.9%
    Swedish Equities2.4%
    Belgian Equities2.4%
    Money Market2.4%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund1%6.4%8.5%18.6%70.3%207.1%
Sector0.4%2.8%3.2%13.7%25.2%44.6%
Rank within sector95 / 55929 / 55920 / 551184 / 53613 / 3971 / 337
Quartile1st1st1st2nd1st1st
Calendar performance
 YTD - 20172016201520142013
Fund5.1%-3.3%12.5%48.6%64.4%
Sector3%11.6%2%7.2%11%
Rank within sector76 / 555494 / 51912 / 4542 / 3922 / 365
Quartile1st4th1st1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
0.04
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
2.56
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.62
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
23.65
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
20.39
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.48
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.41
Price movement
52 week high578.59
52 week low409.45
Current bid price546.31
Current offer price-
Current mid price-
Region
1USA86.21%
2UK2.93%
3Sweden2.44%
4Belgium2.39%
5Money Market2.36%
6France2.1%
7Switzerland0.87%
8Germany0.39%
9Canada0.31%
Industry sector
1Biotechnology/Medical78.77%
2Pharmaceuticals12.96%
3Technology3.7%
4Money Market2.36%
5Electronic & Electrical Equipment1.15%
6Health Care1.06%
Asset type
1US Equities86.21%
2UK Equities2.93%
3Swedish Equities2.44%
4Belgian Equities2.39%
5Money Market2.36%
6French Equities2.1%
7Swiss Equities0.87%
8German Equities0.39%
9Canadian Equities0.31%
Individual holdings
1CELGENE CORP8.9%
2BIOGEN INC8.4%
3GILEAD SCIENCES INC8.2%
4ALEXION PHARMACEUTICALS INC6.8%
5AMGEN INC6%
6INCYTE CORP5%
7VERTEX PHARMACEUTICAL4.5%
8REGENERON PHARMACEUTICALS INC4.2%
9BIOMARIN PHARMACEUTICAL3.7%
Management
Fund manager group
Aviva
Fund manager company
Aviva Life & Pensions UK Ltd
Fund type
Pension Fund
Fund objective
The aim of this Fund is to provide long-term capital growth.
Benchmark
  • NASDAQ Biotechnology
Investment style
No data available.
Investment method
No data available.
Fund managers
NameSinceBiography
Deane Donnigan01/04/2010Deane joined AXA Framlington in October 1997. She currently manages the AXA Framlington Health Fund and AXA Framlington Biotech Fund. Deane attended University of Georgia and the Medical College of Georgia, spending seven years working as a pharmacy intern and a registered pharmacist while working on her BS and PharmD degrees. After this, she worked for 2 years at the Medical College of Georgia Hospital and Clinics with paediatric and adult patients. In 1990, Deane accepted a position with Emory University Hospital, Atlanta, Georgia, as a clinical specialist.
Compliance
No data available.
Domicile
No data available.
Fund for sale in
United Kingdom
Aviva AXA Framlington Biotech Pn Inet
Initial charge-
Annual charge0.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price481.79
CurrencyGBX
Price updated27/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBEI2
Aviva AXA Framlington Biotech Pn S6
Initial charge-
Annual charge0.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price546.31
Offer price-
Mid price-
CurrencyGBX
Price updated27/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBEI1
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.